TY - JOUR
T1 - Understanding Drug Sensitivity and Tackling Resistance in Cancer
AU - The Drug Resistance and Sensitivity Network
AU - Tyner, Jeffrey W.
AU - Haderk, Franziska
AU - Kumaraswamy, Anbarasu
AU - Baughn, Linda B.
AU - Van Ness, Brian
AU - Liu, Song
AU - Marathe, Himangi
AU - Alumkal, Joshi J.
AU - Bivona, Trever G.
AU - Chan, Keith Syson
AU - Druker, Brian J.
AU - Hutson, Alan D.
AU - Nelson, Peter S.
AU - Sawyers, Charles L.
AU - Willey, Christopher D.
N1 - Funding Information:
The work of the Drug Resistance and Sensitivity Network is supported by the NCI Cancer Moonshot under awards U54 CA224019, U54 CA224079, U54 CA224081, U54 CA224018, U54 CA224068, U01 CA217885-03S1, R01 CA131261-09S2, U54 CA224065-02, R01 CA207757-03S1, R01 CA192844-04S1, R37 CA230617-02S1, U01 CA223976-03S1, P50 CA186786-07S1, U01 CA231776-03S1, R01 CA175397-07S1, and U24 CA232979.
Publisher Copyright:
© 2022 The Authors; Published by the American Association for Cancer Research.
PY - 2022/4/15
Y1 - 2022/4/15
N2 - Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the welldocumented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immunesuppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies.
AB - Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the welldocumented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immunesuppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies.
UR - http://www.scopus.com/inward/record.url?scp=85128470935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128470935&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-21-3695
DO - 10.1158/0008-5472.CAN-21-3695
M3 - Review article
C2 - 35195258
AN - SCOPUS:85128470935
SN - 0008-5472
VL - 82
SP - 1448
EP - 1460
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -